|
| |
BioJournal - Medtech Ventures
http://www.bioportfolio.com/cgi-bin/acatalog/Medtech_Ventures.html
 |
It is estimated that approximately 4.5 million people in the developed
word are living with an abdominal aortic aneurysm and each year 600,000 new
cases are diagnosed.
Patients typically have no symptoms and, when they are diagnosed, they often
undergo complex open surgical repair. Stent-graft therapy provides a
minimally-invasive alternative, with reduced recovery times and potentially
improved survival rates. |
 |
An estimated 35,000 thoracic aortic surgical and endovascular
interventions are performed every year in the developed world (10,000 in the
US alone) at a combined cost to individuals, insurance companies and tax
payers of $3.5 billion a year. |
 |
The treatment of Reno-Vascular Disease is currently in a state of
evolution. Current available endovascular devices allow almost all cases of
Renal Artery Stenosis to be successfully opened.
The first successful balloon angioplasty of the Renal Artery was performed
by Andreas Gruntzig in 1976 and over a decade of experience with Renal
Artery Stenting (RAS) has demonstrated that stents can have the same
benefits on acute revascularization of the Renal Arteries, as they do in
virtually all other circulations. |
 |
New and more advanced Retrievable Vena Cava Filters have recently been
developed and introduced resulting in renewed growth and change of dynamics
in this established market.
The majority of traditional Permanent Vena Cava Filters were placed after
failure of anticoagulation to prevent pulmonary embolism (PE). With over 1.2
million PE cases diagnosed in the US & Europe every year and over 300,000
related deaths, medical needs were under-served. |
 |
The market for Fem-Pop Angioplasty & Stenting has experienced explosive
growth recently mainly due to the launch and acceptance of novel atherectomy
devices like the SilverHawk, and the regulatory approval of dedicated Stents.
At the end of 2005 the market was estimated at $470 million, growing by 30%
over the previous year. |
 |
The market for Neuro-Endovascular Devices which currently stands at $590
million is expected to reach $1.1 billion by 2012.
The increase in use of non-invasive neuro-imaging modalities in the
outpatient setting has led to a sharp increase in the number of truly
asymptomatic, intracranial aneurysms being diagnosed.
Continuous improvement in coil design and composition, the introduction of
stents for the management of wide-necked cerebral aneurysms and the
advancement in guiding catheters and wire designs are improving the utility
of coils in intracranial aneurysm repair.
|
 |
Carotid Angioplasty and Stenting (CAS) has recently emerged as a popular
alternative to endarterectomy for the treatment of carotid atherosclerosis.
The recent approval, by the FDA, of carotid artery stents has initiated a
global market in those devices.
Guidant, Boston Scientific, Abbott, Medtronic and J&J have all entered the
market, however, this space still lends itself also to MedTech start-ups
with innovative devices specially in the embolic protection niche. |
 |
Latest research findings indicate that drug eluting stents (DES) reduce
the need for re-intervention after PTCA to a greater extent than bare metal
stents (BMS).
The market for drug eluting stents has shown explosive growth since its
inception and in 2004 it reached an estimated $4.2 billion in revenue
worldwide. |
http://www.bioportfolio.com/cgi-bin/acatalog/sitemap.html
| |
|
